We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Uterine Fibroid Embolization Results in Fewer Complications

By HospiMedica International staff writers
Posted on 11 Apr 2019
Uterine fibroid embolization (UFE) can treat uterine fibroids with fewer complications than surgical myomectomy, according to a new study.

The retrospective study, by researchers at Kaiser Permanente Southern California (KPSC; Pasadena, USA) involved 863 patients with uterine fibroids treated from 2008 to 2015; of these, 451 patients underwent UFE, and the rest a myomectomy. More...
The patients in the UFE group were older (mean age 45 years) than the myomectomy group (39 years), and more of them had multiple and smaller fibroids. The study results showed that women who had myomectomy had a 2.9% rate of blood transfusion, significantly higher than the 1.1% rate for women who had UFE; but 27 patients in the UFE group had adenomyosis, compared to eight patients in the myomectomy group.

In women with pre-procedural anemia, both groups experienced a statistically significant improvement in mean hemoglobin one year after the initial procedure. UFE also resulted in a significantly higher rate of symptomatic improvement in menorrhagia (75.4%) than in the myomectomy group (49.5%). Overall secondary intervention and miscarriage rates were not significantly different between the two groups. The study was presented at the Society of Interventional Radiology (SIR) annual scientific meeting, held during March 2019 in Austin (TX, USA).

“Women with uterine fibroids often are not fully informed of their treatment options, or lack understanding. This point was brought home in a recent survey showing that more than two in five women who have been diagnosed with uterine fibroids have never heard of UFE,” said lead author and study presenter Jemianne Bautista-Jia, PhD. “Women have multiple options available to treat uterine fibroids, and UFE is a beneficial option. UFE is minimally invasive, produces less pain, requires a shorter recovery time, and allows women to get back to their lives sooner.”

A uterine fibroid (leiomyomata) is a benign tumor that originates from smooth muscle (myometrium) in the uterus. The fibroids are often multiple, and if the uterus contains too many to count, it is referred to as diffuse uterine leiomyomatosis. Uterine fibroids are the most common benign tumors in females and typically found during the middle and later reproductive years. While most are asymptomatic, they can grow and cause heavy and painful menstruation, painful sexual intercourse, and urinary frequency and urgency.

Related Links:
Kaiser Permanente Southern California


Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Endoscopy Display
E190
Ultrasound Needle Guidance System
SonoSite L25
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The 3D-printed microneedle patch boosts live-virus vaccine delivery (Photo courtesy of IIS/University of Tokyo)

3D-Printed Delivery System Enhances Vaccine Delivery Via Microneedle Array Patch

The COVID-19 pandemic underscored the need for efficient, durable, and widely accessible vaccines. Conventional vaccination requires trained personnel and cold-chain logistics, which can slow mass immunization... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.